Idioma:

Biologics and systemic lupus erythematosous : new insights and perspectives

Clottu, Aurélie ; Horisberger, Alice ; Comte, Denis

Revue médicale suisse, 2021-04, Vol.17 (733), p.684 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
Biologics and systemic lupus erythematosous : new insights and perspectives
Autor: Clottu, Aurélie ; Horisberger, Alice ; Comte, Denis
Assuntos: B-Lymphocytes ; Biological Products ; Cytokines ; Humans ; Janus Kinase Inhibitors ; Lupus Erythematosus, Systemic - drug therapy
É parte de: Revue médicale suisse, 2021-04, Vol.17 (733), p.684
Descrição: Systemic lupus erythematosus is a complex autoimmune disease that remains challenging to treat. Recent advances in the understanding of the pathogenesis of SLE pave the way for the evaluation of biologic medicine. The most promising therapeutic targets in SLE are those that interfere with B cells count or normal function, interferon inhibitors, JAK inhibitors and biologicals that alter the cytokines imbalance that characterizes SLE. Recent phase 3 clinical trials have evaluated the role of belimumab in lupus nephritis and the usefulness of anifrolumab in the treatment of moderate to severe SLE. Many more trials are currently underway and may improve the level of care of patients with SLE in the near future.
Editor: Switzerland
Idioma: Francês

Links

Voltar para lista de resultados

Anterior Resultado 9 Avançar Ir para próxima página